Following a more than decade-long legal back-and-forth over the generic drug carveout practice known as “skinny” labeling, GSK and Teva have put their dispute to bed, new court documents show. The resolution of this case marks a significant milestone in the ongoing dialogue surrounding the legality and application of skinny labels, which allow generic manufacturers to market their products without infringing on certain patent protections.
This settlement comes at a time when the pharmaceutical industry is increasingly scrutinizing the balance between innovation and competition. The implications of this case extend beyond GSK and Teva, as it sets a precedent that could influence how other companies navigate similar legal challenges. As regulatory bodies continue to refine guidelines on generic drug labeling, stakeholders in the pharma B2B sector must remain vigilant and adaptable to the evolving landscape.
Use the database as your supply chain compass →
